442 related articles for article (PubMed ID: 28342808)
1. Role of mTORC1-S6K1 signaling pathway in regulation of hematopoietic stem cell and acute myeloid leukemia.
Ghosh J; Kapur R
Exp Hematol; 2017 Jun; 50():13-21. PubMed ID: 28342808
[TBL] [Abstract][Full Text] [Related]
2. S6K1 regulates hematopoietic stem cell self-renewal and leukemia maintenance.
Ghosh J; Kobayashi M; Ramdas B; Chatterjee A; Ma P; Mali RS; Carlesso N; Liu Y; Plas DR; Chan RJ; Kapur R
J Clin Invest; 2016 Jul; 126(7):2621-5. PubMed ID: 27294524
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia.
Tabe Y; Tafuri A; Sekihara K; Yang H; Konopleva M
Expert Opin Ther Targets; 2017 Jul; 21(7):705-714. PubMed ID: 28537457
[TBL] [Abstract][Full Text] [Related]
4. Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors.
Altman JK; Sassano A; Kaur S; Glaser H; Kroczynska B; Redig AJ; Russo S; Barr S; Platanias LC
Clin Cancer Res; 2011 Jul; 17(13):4378-88. PubMed ID: 21415215
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab stimulation of ribosomal protein S6 kinase 1 (S6K1) predicts de novo trastuzumab resistance.
Huynh FC; Nguyen D; Jones FE
Biochem Biophys Res Commun; 2017 Jan; 483(1):739-744. PubMed ID: 27993682
[TBL] [Abstract][Full Text] [Related]
6. Cross-talk between sirtuin and mammalian target of rapamycin complex 1 (mTORC1) signaling in the regulation of S6 kinase 1 (S6K1) phosphorylation.
Hong S; Zhao B; Lombard DB; Fingar DC; Inoki K
J Biol Chem; 2014 May; 289(19):13132-41. PubMed ID: 24652283
[TBL] [Abstract][Full Text] [Related]
7. Role of SIRT1 in the growth and regulation of normal hematopoietic and leukemia stem cells.
Li L; Bhatia R
Curr Opin Hematol; 2015 Jul; 22(4):324-9. PubMed ID: 26049753
[TBL] [Abstract][Full Text] [Related]
8. mTORC1 is essential for leukemia propagation but not stem cell self-renewal.
Hoshii T; Tadokoro Y; Naka K; Ooshio T; Muraguchi T; Sugiyama N; Soga T; Araki K; Yamamura K; Hirao A
J Clin Invest; 2012 Jun; 122(6):2114-29. PubMed ID: 22622041
[TBL] [Abstract][Full Text] [Related]
9. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia.
Tamburini J; Green AS; Bardet V; Chapuis N; Park S; Willems L; Uzunov M; Ifrah N; Dreyfus F; Lacombe C; Mayeux P; Bouscary D
Blood; 2009 Aug; 114(8):1618-27. PubMed ID: 19458359
[TBL] [Abstract][Full Text] [Related]
10. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.
Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C
Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165
[TBL] [Abstract][Full Text] [Related]
11. Rictor has a pivotal role in maintaining quiescence as well as stemness of leukemia stem cells in MLL-driven leukemia.
Fang Y; Yang Y; Hua C; Xu S; Zhou M; Guo H; Wang N; Zhao X; Huang L; Yu F; Cheng H; Wang ML; Meng L; Cheng T; Yuan W; Ma D; Zhou J
Leukemia; 2017 Feb; 31(2):414-422. PubMed ID: 27499138
[TBL] [Abstract][Full Text] [Related]
12. Activation of mTORC1 is essential for β-adrenergic stimulation of adipose browning.
Liu D; Bordicchia M; Zhang C; Fang H; Wei W; Li JL; Guilherme A; Guntur K; Czech MP; Collins S
J Clin Invest; 2016 May; 126(5):1704-16. PubMed ID: 27018708
[TBL] [Abstract][Full Text] [Related]
13. The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors.
Fialin C; Larrue C; Vergez F; Sarry JE; Bertoli S; Mansat-De Mas V; Demur C; Delabesse E; Payrastre B; Manenti S; Roche S; Récher C
Leukemia; 2013 Feb; 27(2):325-35. PubMed ID: 22902361
[TBL] [Abstract][Full Text] [Related]
14. Rheb1 promotes tumor progression through mTORC1 in MLL-AF9-initiated murine acute myeloid leukemia.
Gao Y; Gao J; Li M; Zheng Y; Wang Y; Zhang H; Wang W; Chu Y; Wang X; Xu M; Cheng T; Ju Z; Yuan W
J Hematol Oncol; 2016 Apr; 9():36. PubMed ID: 27071307
[TBL] [Abstract][Full Text] [Related]
15. mTORC signaling in hematopoiesis.
Wang X; Chu Y; Wang W; Yuan W
Int J Hematol; 2016 May; 103(5):510-8. PubMed ID: 26791377
[TBL] [Abstract][Full Text] [Related]
16. Elevated protein kinase D3 (PKD3) expression supports proliferation of triple-negative breast cancer cells and contributes to mTORC1-S6K1 pathway activation.
Huck B; Duss S; Hausser A; Olayioye MA
J Biol Chem; 2014 Feb; 289(6):3138-47. PubMed ID: 24337579
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic / mammalian target protein of rapamycin signaling in hematopoietic stem cells and leukemia.
Hirao A; Hoshii T
Cancer Sci; 2013 Aug; 104(8):977-82. PubMed ID: 23648144
[TBL] [Abstract][Full Text] [Related]
18. Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner.
Roffé M; Lupinacci FC; Soares LC; Hajj GN; Martins VR
Cell Signal; 2015 Aug; 27(8):1630-42. PubMed ID: 25889895
[TBL] [Abstract][Full Text] [Related]
19. [Roles of mTORC1 in acute myeloid leukemia].
Hoshii T; Hirao A
Rinsho Ketsueki; 2015 Apr; 56(4):359-65. PubMed ID: 25971265
[TBL] [Abstract][Full Text] [Related]
20. Reciprocal regulation of mTOR complexes in pancreatic islets from humans with type 2 diabetes.
Yuan T; Rafizadeh S; Gorrepati KD; Lupse B; Oberholzer J; Maedler K; Ardestani A
Diabetologia; 2017 Apr; 60(4):668-678. PubMed ID: 28004151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
